COVID-19-associated Guillain-Barré syndrome exhibits distinct NK cell, cytotoxic T-cell, and myeloid immune profiles.

<b>Guillain-Barré syndrome (GBS)</b> is an acute immune-mediated neuropathy often triggered by infections, but its diverse pathophysiological mechanisms are not fully understood. <b>COVID-19-associated GBS (COVID-GBS)</b> is a rare yet severe post-infectious complication, and the specific immune mechanisms driving its development remain unclear. Current understanding of GBS pathogenesis is broad, often implicating humoral and cellular immunity, but the unique immunological signature of COVID-GBS, particularly how it diverges from other GBS forms, represents a critical knowledge gap. Identifying distinct immune mediators could lead to targeted therapeutic strategies.